Preprints from the first round of seroprevalence studies indicate that many more people have been infected with the virus than previously reported. Some of these studies also have serious design flaws.
So-called laboratory-developed tests will eventually face regulations similar to those that currently govern diagnostic tests or kits that are sold to hospitals.